betfred promo code no deposit
Common ingredient in ‘healthy’ diet food could be increasing risk of stroke
A thrill ride manufacturer that has designed a 1,000-foot-tall roller coaster that would shatter all height and speed records is looking for a theme park willing and able to build the towering behemoth. The once-impossible dream of a 1,000-foot-tall coaster is now feasible and in top secret development by an unnamed ridemaker, according to Dennis Speigel, an industry expert with International Theme Park Services . “The project is still under heavy wraps with the final international location yet to be announced,” Speigel wrote on the ITPS website. “But the progress is quite well along and so far is nothing short of breathtaking in every sense of the meaning.” ALSO SEE: Six Flags to spend $1 billion on 11 coasters over next 2 years The 1,000-footer would be twice as tall as any coaster ever built and smash a new record for world’s tallest coaster about to be set in 2025. Six Flags announced in November that its 456-foot-tall Kingda Ka coaster in New Jersey would be removed and replaced by a new record-breaking launch coaster in 2026. The 2005 Kingda Ka held the title of world’s tallest coaster for two decades. ALSO SEE: 5 of the world’s fastest coasters are closed, but a new king will soon rise The 415-foot-tall Superman: Escape from Krypton at Six Flags Magic Mountain now reigns as the tallest operating coaster in the world while the 420-foot-tall Top Thrill 2 coaster at Ohio’s Cedar Point remains closed for repairs. Falcon’s Flight will become the world’s tallest coaster at a skyscraping 640 feet when the new ride debuts in 2025 at Six Flags Quiddiya in Saudi Arabia. ALSO SEE: Coaster war brewing between Six Flags Magic Mountain and relatively unknown European rival Speigel got a sneak preview of the 1,000-foot-tall coaster by the as-yet-unidentified ride manufacturer that swore him to secrecy. Technological advancements in computer- and AI-assisted design have made the pipe dream of a 1,000-foot-tall coaster a very real possiblity, according to Speigel. ALSO SEE: 4 reasons why Universal won’t launch Fast & Furious coaster until 2026 “It’s only a matter of time and financial investment before this aspiration becomes a reality,” Speigel wrote on the ITPS website. The record-setting coaster will need to be built on a swath of land large enough to accommodate the amount of track needed for the launch and run out on either side of the 1,000-foot precipice. ALSO SEE: Six Flags Magic Mountain plans 21st roller coaster for 2026 The structural engineering team behind the project has designed a coaster that can withstand immense vertical and lateral forces, according to Speigel. An “ingenious” braking system will help control the incredible speeds of the coaster that will likely require riders to wear safety goggles, according to Speigel. Related Articles
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows: Abstract Title : PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial Abstract Number: SESS-2211 Session : Concurrent Poster Spotlight Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations Date/Time : Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT) Conference Call Information Relay Therapeutics will host a conference call to discuss these data on Wednesday, December 11, 2024 at 7:00 a.m. ET (6:00 a.m. CT). Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available following the event. The poster will be available at the start of the session on the company’s website at https://relaytx.com/publications/ . About RLY-2608 RLY-2608 is the lead program in Relay Therapeutics’ efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 300,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine. Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation. For more information on RLY-2608, please visit here . About Relay Therapeutics Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics’ strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics’ portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, including lirafugratinib as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics’ use of capital, expenses and potential cost savings. The words “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics’ drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact: Megan Goulart 617-322-0814 mgoulart@relaytx.com Media : Dan Budwick 1AB 973-271-6085 dan@1abmedia.comThe second annual Las Vegas Grand Prix brought over 300,000 F1 fans to Sin City this weekend, but not everyone paid for a ticket. Some crafty spectators found a free and creative way to watch the race by riding an escalator — over and over and over again. captured the hilarious scene outside the Fashion Show Mall as folks took turns riding a set of escalators throughout the race, sneaking glimpses of the action as F1 cars roared past. The escalator’s elevated position overlooks one of the 50-lap spectacle’s most exciting turns, providing a better view than many paid seats at the Las Vegas Strip Circuit. Fans could be seen lining up politely, snapping photos and recording videos as they looped up and down the moving staircase. Security was stationed at the top and bottom of the escalators, but as long as fans kept moving, they weren’t technically breaking any rules. And so, hundreds took advantage of the unconventional setup. Mercedes driver George Russell took first place in the third-last race of the F1 season, with Lewis Hamilton and Carlos Sainz rounding out the podium. But with the average Grand Prix ticket costing $1,617, the escalator riders were arguably the night’s biggest winners. Here’s hoping organizers don’t block off the moving attraction next year.
(The Center Square) – Government attorneys are wrapping up their case with a focus on AT&T and former state Rep. Eddie Acevedo, D-Chicago, at the corruption trial of former Illinois House Speaker Michael Madigan and codefendant Michael McClain. Former Illinois state Rep. Michael McClain and former Illinois House Speaker Michael Madigan separately enter the federal court building in Chicago Wednesday December 11, 2024. Both face corruption charges. Judge John Robert Blakey ruled Wednesday that Acevedo would be required to testify next Monday, despite questions about Acevedo’s competency as a witness. Blakey denied defense attorneys’ motion to quash Acevedo’s subpoena Wednesday morning. Blakey pointed to the distinction between the credibility of the witness and competency to testify. Acevedo’s attorney, Gabrielle Sansonetti, had also sought to prevent Acevedo’s testimony by saying her client had dementia. U.S. government attorneys have introduced evidence showing that Acevedo was paid by AT&T and ComEd for do-nothing jobs. In a separate case, Acevedo was sentenced in 2022 to six months in prison for tax evasion. Lobbyist Thomas Cullen, who worked for Madigan from 1987 to 1999 in both the Speaker’s office and the Democratic Party of Illinois, reported to the witness stand Wednesday afternoon. Prosecutors say AT&T made payments to Acevedo through Cullen’s lobbying firm. Cullen said his attorney, Thomas Durkin, requested a non-target letter from the government to indicate that Cullen is not the target of the investigation corresponding with the trial of Madigan and McClain. Cullen called himself a “political junkie” and said he was loyal to the speaker and loyal to Democrats. Cullen said McClain would ask him to go to his clients and request campaign donations for Illinois Democrats in target districts. Government attorney Sarah Streicker displayed a transcript of a recording from Aug. 29, 2018, of McClain asking Cullen, on behalf of “our mutual friend,” to join him and others in donating $1,000 each per month for six months to former Madigan aide Kevin Quinn, who had been dismissed over harassment claims. Cullen said he understood “our mutual friend” to mean Mike Madigan and agreed emphatically to McClain’s request, even though Cullen said there were no unique services that Quinn could provide for him. During the call, McClain said that Madigan would “take care of Kevin” once Madigan was sworn in as speaker. Cullen testified that Kevin Quinn was an effective member of Madigan’s 13th Ward Democratic Organization in Chicago. Cullen said he paid Quinn $1,000 per month for six months. Cullen said he helped AT&T talk with Illinois lawmakers about carrier-of-last-resort legislation. According to Cullen, a COLR bill was AT&T’s No. 1 priority in 2017. The legislation passed that summer. Streicker asked Cullen about Acevedo, who had served as an assistant majority leader for Democratic members of the Illinois House under Madigan until Acevedo left the General Assembly in 2017. Cullen said AT&T did not want Acevedo’s successor, Theresa Mah, D-Chicago, to know that the company was paying Acevedo, because Mah had defeated Acevedo’s son in a contentious campaign. Cullen said he agreed to hire Acevedo even though he did not think Acevedo could add anything of value to his firm. “He wasn’t a serious member of the General Assembly ... I didn’t think he could add anything to my team,” Cullen added. Cullen described a meeting during which Acevedo “got mad” and used “some choice words” because he was upset that AT&T was being “cheap” by only offering him $2,500 per month. Prosecutors called AT&T Illinois employee Barbara Galvin to the witness stand Wednesday morning. Galvin said she has worked in the company’s external and legislative affairs department since 2003. Government attorney Amar Bhachu introduced a 2017 consultant agreement with Cullen’s firm to work under the direction of AT&T President Paul La Schiazza. According to the agreement, Cullen’s firm did not have authority to give gifts or payments directly or indirectly to political officials or parties. Bhachu also displayed an amendment to the deal that raised the payment amount to Cullen’s firm from $7,500 per month to $10,000 per month. Bhachu then introduced an email among AT&T legislative affairs members explaining the increased payments for an additional asset, which Galvin testified was “Eddie Acevedo,” to support House Democratic leadership. Bhachu then showed jurors a document showing AT&T’s sponsorship of a fundraising event for Aunt Martha’s Health & Wellness in Chicago “to provide stakeholder opportunities with legislators.” The document included language explaining the $2,500 cost of the event, to align with Aunt Martha’s, was “to position AT&T with state, city and county decision-makers and business leaders.” FBI Special Agent Jennifer Avila followed Galvin to the witness stand and testified about AT&T records related to the company’s efforts to lobby Madigan for telecommunications modernization. Prosecutors introduced several emails over prior objections by the defense teams. In one email, La Schiazza wrote, “In Illinois no bill can get through the legislature and to the Governor without the tacit approval of the all-powerful House Speaker Michael Madigan. He is the longest serving Speaker in the United States and rules the House with an iron fist.” Another email from La Schiazza asked if there was money set aside for Eddie Acevedo. A subsequent email recommended that Acevedo not be contracted directly with AT&T but instead be hired by Cullen’s firm. In a series of emails, AT&T executives indicated that Acevedo “felt insulted” by the company’s consulting offer of $2,500 per month and asked for $3,000 per month. Acevedo eventually accepted the $2500 amount for consulting through Cullen & Associates. Government attorney Julia Schwartz introduced a series of emails from the summer of 2017, after the General Assembly passed legislation favored by AT&T. In one email, the speaker’s son, Andrew Madigan, emailed AT&T officials to invite them to participate in a fundraiser for Aunt Martha’s. La Schiazza suggested that this would not be the last such request and, after some discussion via email, La Schiazza wrote, “We’re on the friends and family plan now.” Connie Mixon, professor of Political Science and director of the Urban Studies Program at Elmhurst University, said defense attorneys might argue that AT&T’s behavior is not unusual. “Most people, most organizations, most corporations try to curry favor with legislators and, importantly, the powerful Speaker of the Illinois House, Michael Madigan,” Mixon told The Center Square. Lobbyist and former Madigan aide Will Cousineau mentioned AT&T in a wiretapped call with McClain on May 25, 2018. “Zalewski was asked to get you language on his small cell item today?” Cousineau asked. “Yeah?” McClain said. “Was that to talk to, to start a discussion with AT&T? And here’s the reason I’m asking: I’ve got a little, uh, COLR relief for little Century Link in there, um, that I would like to hook to anything that moves, and it’s in the language that he got you,” Cousineau said. Former AT&T executive Deno Perdiou began testifying Tuesday afternoon but did not return Wednesday due to what Blakey called “a personal issue.” The court is not scheduled to be in session Thursday or Friday. Trial proceedings are scheduled to resume Monday morning at the Everett McKinley Dirksen U.S. Courthouse in Chicago. Prosecutors indicated that they expect to rest their case Tuesday. Madigan’s defense attorneys suggested they would be ready to begin presenting their case when the government rests. Attorneys mentioned that state Rep. Bob Rita, D-Blue Island, might return to the witness stand. Rita testified for about 10 minutes on Oct. 24 but did not return. Bhachu said there are “some things in play” with regard to Rita. Madigan and McClain are charged with 23 counts of bribery, racketeering and official misconduct in connection with a scheme U.S. government attorneys termed, “The Madigan Enterprise.” Prosecutors allege that ComEd and AT&T Illinois gave out no-work or little-work jobs and contract work to those loyal to Madigan to get legislation passed that would benefit them in Springfield. Four ComEd executives and lobbyists were convicted last year in a related trial, and ComEd itself agreed to pay $200 million in fines as part of a deferred prosecution agreement with prosecutors.
San Francisco 49ers quarterback Brock Purdy will not play Sunday and head coach Kyle Shanahan said the lingering discomfort is a concern. Purdy sat out Friday after he participated in the start of Thursday's practice with the 49ers, then retreated indoors for what Shanahan said was a treatment session. Brandon Allen, 32, will start in Purdy's place, and the 49ers are also without defensive end Nick Bosa (oblique). Shanahan said players believe in Allen, even if he's an unknown. "Outside of here people haven't seen a lot of Brandon. But it's his second year (with the 49ers)," Shanahan said. "Obviously guys want Brock up, but guys are excited to see Brandon play." Shanahan said they are "a little surprised" Purdy experienced tightness and discomfort in his shoulder after an MRI exam on Monday that showed no long-term cause for concern. "The way it responded this week, it's really up in the air for next week," Shanahan said of Purdy. Allen is familiar to Packers head coach Matt LaFleur, who was an assistant coach with the Rams during Allen's two-year run in Los Angeles. Allen broke into the NFL in 2016 with the Jaguars and is 2-7 in nine career starts. He went 1-2 with the Broncos in 2019 and 1-5 in six starts over two years with the Bengals in 2020 and ‘21. Shanahan said Allen's confidence grew throughout the week and he doesn't anticipate a major change in how he calls the offense. Left tackle Trent Williams (ankle) also missed practice for the third consecutive day. Without disclosing the nature of the ailment to Purdy's throwing shoulder, general manager John Lynch confirmed Friday an MRI exam took place to determine the severity of any injury. Allen worked with the first team most of Thursday and Friday with Joshua Dobbs also taking snaps. Lynch described Purdy's status for the 49ers (5-5) this week as "tenuous." "Hopefully, he makes progress, and we can have a shot at this weekend, but we'll see," Lynch said in an interview with KNBR in San Francisco. "I think it's tenuous." When Purdy was on the field this week, he primarily worked on the side in position-specific drills with QB coach Brian Griese. Williams played through an ankle injury last week after being listed as questionable but exited the stadium with an exaggerated limp on Sunday. Run game coordinator Chris Foerster said the 49ers aren't where they want to be at 5-5 because they haven't won close games, not because of injuries. "Seven games left is like an eternity," Foerster said. "So much can happen. Do the math. What was our record last year? It was 12-5. I was on a 13-win team that was nowhere near as good as the team last year." With or without Purdy, Foerster said the challenge for the 49ers is not to give up the ball to a defense that has 19 takeaways. The 49ers have 13 giveaways this season. --Field Level MediaNIO Stock Price 2025 Prediction: Will NIO Fall Even Further Next Year?
NonePHILADELPHIA (AP) — Former Temple basketball standout Hysier Miller sat for a long interview with the NCAA as it looked into concerns about unusual gambling activity, his lawyer said Friday amid reports a federal probe is now under way. “Hysier Miller fully cooperated with the NCAA’s investigation. He sat for a five-hour interview and answered every question the NCAA asked. He also produced every document the NCAA requested,” lawyer Jason Bologna said in a statement. “Hysier did these things because he wanted to play basketball this season, and he is devastated that he cannot.” Miller, a three-year starter from South Philadelphia, transferred to Virginia Tech this spring. However, the Hokies released him last month due to what the program called “circumstances prior to his enrollment at Virginia Tech.” Bologna declined to confirm that a federal investigation had been opened, as did spokespeople for both the FBI and the U.S. Attorney’s Office in Philadelphia. ESPN, citing unnamed sources, reported Thursday that authorities were investigating whether Miller bet on games he played in at Temple, and whether he adjusted his performance accordingly. “Hysier Miller has overcome more adversity in his 22 years than most people face in their lifetime. He will meet and overcome whatever obstacles lay ahead,” Bologna said. Miller scored eight points — about half his season average of 15.9 — in a 100-72 loss to UAB on March 7 that was later flagged for unusual betting activity. Temple said it has been aware of those allegations since they became public in March, and has been cooperative. “We have been fully responsive and cooperative with the NCAA since the moment we learned of the investigation,” Temple President John Fry said in a letter Thursday to the school community. However, Fry said Temple had not received any requests for information from state or federal law enforcement agencies. He vowed to cooperate fully if they did. “Coaches, student-athletes and staff members receive mandatory training on NCAA rules and regulations, including prohibitions on involvement in sports wagering,” Fry said in the letter. The same week the Temple-UAB game raised concerns, Loyola (Maryland) said it had removed a person from its basketball program after it became aware of a gambling violation. Temple played UAB again on March 17, in the finals of the American Athletic Conference Tournament. League spokesman Tom Fenstermaker also declined comment on Friday. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up . AP college basketball: and
Google’s new AI projects aren’t ready for the masses yet. Good!
This Iron Condor Gives Nuclear Oklo Stock A Wide Range For Profit
Best TV of 2024: A modestly better lineup than usual, but why didn’t it feel that way?Person accused of accosting Rep. Nancy Mace at Capitol pleads not guilty to assault charge
NoneWASHINGTON (AP) — A person accused of accosting U.S. Rep. Nancy Mace in a Capitol Office building pleaded not guilty on Wednesday to a misdemeanor assault charge. Witnesses told police that James McIntyre, 33, of Chicago, shook Mace's hand in an “exaggerated, aggressive” manner after approaching the South Carolina Republican in the Rayburn House Office Building on Tuesday evening, according to a police affidavit. Mace, who is identified only by her initials in a court filing, posted a string of social media messages about the incident. She said she was “physically accosted” at the Capitol, and she thanked President-elect Donald Trump for calling her Wednesday morning to check on her condition. “I’m going to be fine just as soon as the pain and soreness subside,” Mace wrote. Mace declined to be treated by a paramedic after her encounter with McIntyre, who was arrested Tuesday by the Capitol Police, the affidavit says. Mace told police that McIntyre said, “Trans youth serve advocacy,” while shaking her hand. Last month, Mace proposed a resolution that would prohibit any lawmakers and House employees from “using single-sex facilities other than those corresponding to their biological sex.” Mace said the bill is aimed specifically at Delaware Democrat Sarah McBride — the first transgender person to be elected to Congress. A magistrate judge ordered McIntyre’s release after an arraignment in Superior Court of the District of Columbia. Efforts to reach an attorney for McIntyre weren't immediately successful.
Person accused of accosting Rep. Nancy Mace at Capitol pleads not guilty to assault chargePilenko's four decades of energy and infrastructure expertise adds operational leadership depth as LanzaTech continues global deployment and scaling of its carbon management solution CHICAGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (NASDAQ: LNZA) ("LanzaTech” or the "Company”), the carbon recycling company transforming above-ground carbon into sustainable fuels, chemicals, materials, and protein, today announced the appointment of Thierry Pilenko, former Executive Chairman of TechnipFMC plc ("TechnipFMC”), to its Board of Directors. With more than 40 years of experience in the energy and industrial sectors, Pilenko brings invaluable expertise and leadership related to large-scale infrastructure development, technology deployment, and profitable growth. Pilenko's extensive experience and industry acumen are expected to provide valuable guidance as LanzaTech advances the commercial deployment of its technology and accelerates its timeline to profitability. "We are thrilled to welcome Thierry to our Board of Directors,” said LanzaTech Chair and CEO Dr. Jennifer Holmgren. "His proven track record of deploying innovative technologies and driving large-scale infrastructure projects will bring key insights as we execute LanzaTech's ambitious growth strategy. Thierry spent the first 20 years of his career with Schlumberger Limited, deploying technologies on five continents. He then continued on to become a seasoned public company executive who successfully led TechnipFMC, Technip, and Veritas DGC. Throughout his exceptional career, Thierry developed a deep understanding of the global industrial landscape and the evolving competitive dynamics of the energy industry and the energy transition. Thierry's operational leadership in global, complex and capital-intensive industries is central to advancing our mission to provide resilient, reliable technology that advances above-ground carbon recycling and produces commercial-scale ethanol that can be used in a wide range of applications, including sustainable aviation fuel.” During his tenure as Executive Chairman of TechnipFMC, and Chairman and CEO of Technip, Thierry led a large global team delivering energy solutions across 45 countries and was pivotal in overseeing Technip's transformation and merger with FMC Technologies. This merger demonstrated the power of integration to significantly reduce costs and improve economics of large-scale projects while reducing corporate overhead costs. Under Pilenko's leadership, Technip successfully executed landmark projects such as Shell's $12 billion Prelude floating LNG facility and the $20+ billion Yamal LNG project. "It is an honor to join LanzaTech's Board of Directors and contribute to the company's pioneering and commercially proven carbon management solution,” said Pilenko. "Having spent my career in the energy sector, I understand the critical importance of deploying replicable technology solutions and know first-hand what it takes to successfully put steel in the ground and achieve desired returns. LanzaTech's innovative approach to carbon reuse offers a unique and proven solution that will have a substantial impact on the energy transition. I am deeply committed to advancing these technologies and ensuring their widespread adoption for a more sustainable future.” In addition to joining LanzaTech's Board, Pilenko currently serves on the boards of Arkema, a leading specialty materials company, and Trident Energy, an oil and gas production company. He is also the Board Chair of Rely, a green hydrogen-focused joint venture, and a co-founder of P6 Technologies, a SaaS platform for carbon lifecycle analysis. The appointment of Pilenko as an independent director increases LanzaTech's board of directors to seven members, filling a previously vacant seat and further strengthening the Company's corporate governance. About LanzaTech LanzaTech Global, Inc. (NASDAQ: LNZA) is the carbon recycling company transforming waste carbon into sustainable fuels, chemicals, materials, and protein for everyday products. Using its biorecycling technology, LanzaTech captures carbon generated by energy-intensive industries at the source, preventing it from being emitted into the air. LanzaTech then gives that captured carbon a new life as a clean replacement for virgin fossil carbon in everything from household cleaners and clothing fibers to packaging and fuels. By partnering with companies across the global supply chain like ArcelorMittal, Coty, Craghoppers, REI, and LanzaJet, LanzaTech is paving the way for a circular carbon economy. For more information about LanzaTech, visit https://lanzatech.com. Forward Looking Statements This press release includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of LanzaTech. These statements are based on the beliefs, assumptions, projections and conclusions of LanzaTech's management. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, many of which are outside LanzaTech's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. LanzaTech cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are not guarantees of future performance, conditions or results, and you should not rely on forward-looking statements. Generally, statements that are not historical facts, including those concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes,” "estimates,” "expects,” "projects,” "forecasts,” "may,” "will,” "should,” "seeks,” "plans,” "scheduled,” "anticipates,” "intends” or similar expressions. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: timing delays in the advancement of projects to the final investment decision stage or into construction; failure by customers to adopt new technologies and platforms; fluctuations in the availability and cost of feedstocks and other process inputs; the availability and continuation of government funding and support; broader economic conditions, including inflation, interest rates, supply chain disruptions, employment conditions, and competitive pressures; unforeseen technical, regulatory, or commercial challenges in scaling proprietary technologies, business functions or operational disruptions; and other economic, business, or competitive factors, and other risks and uncertainties, including the risk factors and other information contained in LanzaTech's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, as well as other existing and future filings with the U.S. Securities and Exchange Commission. Any forward-looking statement herein is based only on information currently available to LanzaTech and speaks only as of the date on which it is made. LanzaTech undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Relations Kate Walsh VP, Investor Relations & Tax [email protected] Media Relations Kit McDonnell Director of Communications [email protected]
Warren Buffett gives away another $1.1B and plans for distributing his $147B fortune after his deathBy REBECCA SANTANA WASHINGTON (AP) — President-elect Donald Trump has promised to end birthright citizenship as soon as he gets into office to make good on campaign promises aiming to restrict immigration and redefining what it means to be American. But any efforts to halt the policy would face steep legal hurdles. Birthright citizenship means anyone born in the United States automatically becomes an American citizen. It’s been in place for decades and applies to children born to someone in the country illegally or in the U.S. on a tourist or student visa who plans to return to their home country. It’s not the practice of every country, and Trump and his supporters have argued that the system is being abused and that there should be tougher standards for becoming an American citizen. But others say this is a right enshrined in the 14th Amendment to the Constitution, it would be extremely difficult to overturn and even if it’s possible, it’s a bad idea. Here’s a look at birthright citizenship, what Trump has said about it and the prospects for ending it: During an interview Sunday on NBC’s “Meet the Press” Trump said he “absolutely” planned to halt birthright citizenship once in office. “We’re going to end that because it’s ridiculous,” he said. Trump and other opponents of birthright citizenship have argued that it creates an incentive for people to come to the U.S. illegally or take part in “birth tourism,” in which pregnant women enter the U.S. specifically to give birth so their children can have citizenship before returning to their home countries. “Simply crossing the border and having a child should not entitle anyone to citizenship,” said Eric Ruark, director of research for NumbersUSA, which argues for reducing immigration. The organization supports changes that would require at least one parent to be a permanent legal resident or a U.S. citizen for their children to automatically get citizenship. Others have argued that ending birthright citizenship would profoundly damage the country. “One of our big benefits is that people born here are citizens, are not an illegal underclass. There’s better assimilation and integration of immigrants and their children because of birthright citizenship,” said Alex Nowrasteh, vice president for economic and social policy studies at the pro-immigration Cato Institute. In 2019, the Migration Policy Institute estimated that 5.5 million children under age 18 lived with at least one parent in the country illegally in 2019, representing 7% of the U.S. child population. The vast majority of those children were U.S. citizens. The nonpartisan think tank said during Trump’s campaign for president in 2015 that the number of people in the country illegally would “balloon” if birthright citizenship were repealed, creating “a self-perpetuating class that would be excluded from social membership for generations.” In the aftermath of the Civil War, Congress ratified the 14th Amendment in July 1868. That amendment assured citizenship for all, including Black people. “All persons born or naturalized in the United States and subject to the jurisdiction thereof, are citizens of the United States and of the State wherein they reside,” the 14th Amendment says. “No State shall make or enforce any law which shall abridge the privileges or immunities of citizens of the United States.” But the 14th Amendment didn’t always translate to everyone being afforded birthright citizenship. For example, it wasn’t until 1924 that Congress finally granted citizenship to all Native Americans born in the U.S. A key case in the history of birthright citizenship came in 1898, when the U.S. Supreme Court ruled that Wong Kim Ark, born in San Francisco to Chinese immigrants, was a U.S. citizen because he was born in the states. The federal government had tried to deny him reentry into the county after a trip abroad on grounds he wasn’t a citizen under the Chinese Exclusion Act. But some have argued that the 1898 case clearly applied to children born of parents who are both legal immigrants to America but that it’s less clear whether it applies to children born to parents without legal status or, for example, who come for a short-term like a tourist visa. “That is the leading case on this. In fact, it’s the only case on this,” said Andrew Arthur, a fellow at the Center for Immigration Studies, which supports immigration restrictions. “It’s a lot more of an open legal question than most people think.” Some proponents of immigration restrictions have argued the words “subject to the jurisdiction thereof” in the 14th Amendment allows the U.S. to deny citizenship to babies born to those in the country illegally. Trump himself used that language in his 2023 announcement that he would aim to end birthright citizenship if reelected. Trump wasn’t clear in his Sunday interview how he aims to end birthright citizenship. Asked how he could get around the 14th Amendment with an executive action, Trump said: “Well, we’re going to have to get it changed. We’ll maybe have to go back to the people. But we have to end it.” Pressed further on whether he’d use an executive order, Trump said “if we can, through executive action.” He gave a lot more details in a 2023 post on his campaign website . In it, he said he would issue an executive order the first day of his presidency, making it clear that federal agencies “require that at least one parent be a U.S. citizen or lawful permanent resident for their future children to become automatic U.S. citizens.” Related Articles National Politics | Trump has flip-flopped on abortion policy. His appointees may offer clues to what happens next National Politics | In promising to shake up Washington, Trump is in a class of his own National Politics | Election Day has long passed. In some states, legislatures are working to undermine the results National Politics | Trump taps his attorney Alina Habba to serve as counselor to the president National Politics | Massachusetts Democrat Seth Moulton bashes local media for trying to ‘inflame’ LGBTQ remarks Trump wrote that the executive order would make clear that children of people in the U.S. illegally “should not be issued passports, Social Security numbers, or be eligible for certain taxpayer funded welfare benefits.” This would almost certainly end up in litigation. Nowrasteh from the Cato Institute said the law is clear that birthright citizenship can’t be ended by executive order but that Trump may be inclined to take a shot anyway through the courts. “I don’t take his statements very seriously. He has been saying things like this for almost a decade,” Nowrasteh said. “He didn’t do anything to further this agenda when he was president before. The law and judges are near uniformly opposed to his legal theory that the children of illegal immigrants born in the United States are not citizens.” Trump could steer Congress to pass a law to end birthright citizenship but would still face a legal challenge that it violates the Constitution. Associated Press reporter Elliot Spagat in San Diego contributed to this report.